LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

Home・Aktien・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Geschlossen

4.4 -0.45

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.3

Max

4.46

Schlüsselkennzahlen
By Trading Economics
Einkommen	-10M -7.7M
Verkäufe	-10M 529K
EPS	-0.056
Gewinnspanne	-1,463.516
Angestellte	44
EBITDA	-10M -7.7M

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-70M 810M
Vorheriger Eröffnungskurs	4.85
Vorheriger Schlusskurs	4.4

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

3.255 / 3.365 Unterstützung & Widerstand

Arbutus Biopharma Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Dez. 2025, 20:41 UTC

Ergebnisse

Wichtige Markttreiber

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4. Dez. 2025, 18:14 UTC

Akquisitionen, Fusionen, Übernahmen

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4. Dez. 2025, 17:43 UTC

Wichtige Markttreiber

Akquisitionen, Fusionen, Übernahmen

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4. Dez. 2025, 17:01 UTC

Ergebnisse

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4. Dez. 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4. Dez. 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. Dez. 2025, 21:54 UTC

Market Talk

Global Equities Roundup: Market Talk

4. Dez. 2025, 21:54 UTC

Market Talk

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4. Dez. 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. Dez. 2025, 21:48 UTC

Market Talk

Scales Hits Mark With Earnings Guidance -- Market Talk

4. Dez. 2025, 21:37 UTC

Ergebnisse

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4. Dez. 2025, 21:36 UTC

Ergebnisse

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4. Dez. 2025, 20:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. Dez. 2025, 20:15 UTC

Market Talk

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4. Dez. 2025, 20:04 UTC

Market Talk

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4. Dez. 2025, 19:54 UTC

Market Talk

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4. Dez. 2025, 19:44 UTC

Akquisitionen, Fusionen, Übernahmen

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4. Dez. 2025, 19:44 UTC

Akquisitionen, Fusionen, Übernahmen

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4. Dez. 2025, 19:44 UTC

Akquisitionen, Fusionen, Übernahmen

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4. Dez. 2025, 19:33 UTC

Market Talk

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4. Dez. 2025, 19:01 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4. Dez. 2025, 19:01 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4. Dez. 2025, 19:01 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4. Dez. 2025, 19:01 UTC

Akquisitionen, Fusionen, Übernahmen

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4. Dez. 2025, 18:58 UTC

Market Talk

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4. Dez. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. Dez. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. Dez. 2025, 16:41 UTC

Market Talk

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4. Dez. 2025, 16:33 UTC

Market Talk

Ergebnisse

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Peer-Vergleich

Kursveränderung

Arbutus Biopharma Corp Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Arbutus Biopharma Corp – Dist abgegeben haben.

Technischer Score

By Trading Central

3.255 / 3.365Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.